| Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus … P Dorr, M Westby, S Dobbs, P Griffin, B Irvine, M Macartney, J Mori, ... Antimicrobial agents and chemotherapy 49 (11), 4721-4732, 2005 | 1543 | 2005 |
| Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist K Beaumont, R Webster, I Gardner, K Dack Current drug metabolism 4 (6), 461-485, 2003 | 538 | 2003 |
| PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies R Webster, E Didier, P Harris, N Siegel, J Stadler, L Tilbury, D Smith Drug Metabolism and Disposition 35 (1), 9-16, 2007 | 410 | 2007 |
| Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches NA Hosea, WT Collard, S Cole, TS Maurer, RX Fang, H Jones, SM Kakar, ... The Journal of Clinical Pharmacology 49 (5), 513-533, 2009 | 311 | 2009 |
| PEGylated protein drugs: basic science and clinical applications FM Veronese Springer Science & Business Media, 2009 | 219 | 2009 |
| PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals R Webster, V Elliott, BK Park, D Walker, M Hankin, P Taupin PEGylated protein drugs: Basic science and clinical applications, 127-146, 2009 | 218 | 2009 |
| A comprehensive non‐clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder E Callegari, B Malhotra, PJ Bungay, R Webster, KS Fenner, S Kempshall, ... British journal of clinical pharmacology 72 (2), 235-246, 2011 | 195 | 2011 |
| Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. R Webster, D Leishman, D Walker Current opinion in drug discovery & development 5 (1), 116-126, 2002 | 149 | 2002 |
| The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development DK Walker British journal of clinical pharmacology 58 (6), 601-608, 2004 | 133 | 2004 |
| Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate CE Mowbray, C Burt, R Corbau, S Gayton, M Hawes, M Perros, I Tran, ... Bioorganic & medicinal chemistry letters 19 (20), 5857-5860, 2009 | 120 | 2009 |
| The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691) MD Fidock, BE Souberbielle, C Laxton, J Rawal, O Delpuech‐Adams, ... Clinical Pharmacology & Therapeutics 89 (6), 821-829, 2011 | 88 | 2011 |
| Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary … PA Glossop, CAL Lane, DA Price, ME Bunnage, RA Lewthwaite, K James, ... Journal of medicinal chemistry 53 (18), 6640-6652, 2010 | 82 | 2010 |
| Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl) guanidines PV Fish, CG Barber, DG Brown, R Butt, MG Collis, RP Dickinson, ... Journal of medicinal chemistry 50 (10), 2341-2351, 2007 | 78 | 2007 |
| Potent and selective nonpeptidic inhibitors of procollagen C-proteinase PV Fish, GA Allan, S Bailey, J Blagg, R Butt, MG Collis, D Greiling, ... Journal of medicinal chemistry 50 (15), 3442-3456, 2007 | 76 | 2007 |
| PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans R Webster, R Xie, E Didier, R Finn, J Finnessy, A Edgington, D Walker Xenobiotica 38 (10), 1340-1351, 2008 | 74 | 2008 |
| Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction … G Allan, J Davis, M Dickins, I Gardner, T Jenkins, H Jones, R Webster, ... Xenobiotica 38 (6), 620-640, 2008 | 68 | 2008 |
| Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays LH Jones, G Allan, O Barba, C Burt, R Corbau, T Dupont, T Knöchel, ... Journal of medicinal chemistry 52 (4), 1219-1223, 2009 | 66 | 2009 |
| Structural pairwise comparisons of HLM stability of phenyl derivatives: introduction of the Pfizer metabolism index (PMI) and metabolism-lipophilicity efficiency (MLE) ML Lewis, L Cucurull-Sanchez Journal of computer-aided molecular design 23 (2), 97-103, 2009 | 63 | 2009 |
| Microbial oxidative metabolism of diclofenac: production of 4′-hydroxydiclofenac using Epiccocum nigrum IMI354292 R Webster, M Pacey, T Winchester, P Johnson, S Jezequel Applied microbiology and biotechnology 49, 371-376, 1998 | 60 | 1998 |
| The discovery of long acting β2-adrenoreceptor agonists AD Brown, ME Bunnage, PA Glossop, K James, R Jones, CAL Lane, ... Bioorganic & medicinal chemistry letters 17 (14), 4012-4015, 2007 | 51 | 2007 |
